Merck & Co., Inc.
Explore Merck & Co., Inc.
Core profile pages, annual revenue records, and related research hubs for this company.
CorpDigest
Merck & Co., Inc.
Explore Merck & Co., Inc.
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$65B
Market Cap
$215.0B
Net Income
$15.6B
Employees
74,000
Revenue ran at $48.7 billion in FY2021, $59.3 billion in FY2022, $58.5 billion in FY2023, and $65B in FY2025. The FY2024 increase was driven by Keytruda volume growth across expanding indications. Net income of $15.62 billion in FY2024 implied a 24.6% net margin — high for a company that invests approximately $16.4 billion annually in R&D, representing roughly 26% of net sales. Merck's R&D intensity — 26% of net sales dedicated to research — is one of the highest among large-cap pharmaceutical companies globally. The approximately $16.4 billion invested in FY2024 funds Keytruda's more than 1,600 active clinical studies, pipeline assets in cardiovascular disease, oncology, vaccines, and infectious disease, and the early-stage discovery programs that will define the company's revenue base after 2028. Market capitalization of $215 billion against $63.6 billion in revenue reflects both the current profitability and the market's assessment of the Keytruda cliff risk. Biosimilar pembrolizumab will eventually enter the market after the US exclusivity expires around 2028, and the revenue erosion curve for biosimilar biologics is genuinely uncertain — slower than small molecule generics, but real. Every acquisition Merck has made in recent years is partly an attempt to pre-fund the post-Keytruda revenue base. The Vioxx withdrawal in 2004 and the resulting $4.85 billion liability settlement remains the most financially damaging product safety event in the company's history. The Inflation Reduction Act legal challenge over Januvia pricing and the Gardasil China pullback in 2023 represent newer regulatory and market access risks that run in parallel with the Keytruda cliff as material financial considerations.
Revenue Trend Analysis
YoY Change
+2.2%
7-Year CAGR
+6.3%
Peak Year
2025
Trend
Consistent Growth
Merck & Co., Inc. has reported revenue across 8 fiscal years, compounding at +6.3% annually over 7 years. The most recent year saw a 2.2% increase versus the prior year. Revenue peaked in 2025 at $65.0B. Out of 7 reported periods, 7 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $65.0B | — | +2.2% |
| FY2024 | $63.6B | $17.1B | +5.8% |
| FY2023 | $60.1B | $365M | +1.4% |
| FY2022 | $59.3B | $14.5B | +21.7% |
| FY2021 | $48.7B | $13.0B | +1.5% |
| FY2020 | $48.0B | $7.1B | +2.5% |
| FY2019 | $46.8B | $9.8B | +10.7% |
| FY2018 | $42.3B | $6.2B | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Merck's revenue grew from $48.0 billion in fiscal year 2020 to $48.7 billion in 2021, then accelerated sharply to $59.3 billion in 2022 and $58.5 billion in 2023 before reaching $63.6 billion in fiscal year 2024. The acceleration from 2021 to 2022 was driven predominantly by Keytruda's expanding approvals and growing market penetration across oncology indications, combined with post-pandemic normalization of healthcare utilization. The modest dip from 2022 to 2023 reflected the Gardasil China revenue headwind — a significant pullback in Chinese government procurement of the HPV vaccine — partially offset by continued Keytruda growth. The FY2024 increase to $63.6 billion reflects Keytruda approaching $25+ billion in annual sales, the commercial launch of Winrevair for pulmonary arterial hypertension, and sustained Animal Health performance. Net income in FY2024 was approximately $15.6 billion, implying a 24.6% net margin — a high figure given that Merck simultaneously invested approximately $16.4 billion in R&D, representing 26% of net sales. The combination of high absolute revenue, 25%+ net margins, and continuing R&D reinvestment reflects the commercial leverage of Keytruda operating at peak while the patent cliff is still several years away.
Merck invested approximately $16.4 billion in research and development in fiscal year 2024, representing roughly 26% of net sales — one of the highest R&D intensity ratios among large-cap global pharmaceutical companies. By comparison, AstraZeneca spends approximately 24–25% of revenue on R&D, Roche approximately 20–22%, and Johnson & Johnson's pharmaceutical segment approximately 18–20%. The spending funds three categories. First, Keytruda's clinical program: over 1,600 active studies involving more than 300,000 patients globally — designed to expand approved indications, test combination therapies, and accumulate the clinical evidence that reinforces the drug's market position. Second, late-stage pipeline: tulisokibart (PRA023, TL1A antibody for inflammatory bowel disease from the Prometheus acquisition), sotatercept/Winrevair clinical work across PAH indications, and additional candidates in cardiovascular, infectious disease, and oncology. Third, early discovery: the internal research pipeline that will define Merck's revenue base in the 2030s. The $16.4 billion investment represents a massive bet that internal and acquired pipeline assets can generate enough revenue after 2028 to replace the portion of Keytruda income lost to biosimilar competition. The R&D budget has grown substantially since 2019 to reflect the urgency of this pipeline-building mandate.
Between 2021 and 2023, Merck deployed approximately $22 billion in two transformative acquisitions. The $11.5 billion acquisition of Acceleron Pharma in 2021 secured the rights to sotatercept, an activin signaling inhibitor that became Winrevair — approved for pulmonary arterial hypertension in 2024. PAH is a severe, progressive disease with limited treatment options and high pricing power; analysts project Winrevair could reach $5–7 billion in peak annual sales. The $10.8 billion acquisition of Prometheus Biosciences in 2023 acquired PRA023 (tulisokibart), an anti-TL1A antibody in late-stage clinical development for ulcerative colitis and Crohn's disease. Inflammatory bowel disease is a large commercial market: Humira generated over $20 billion annually at its peak, and the IBD treatment market is entering a new generation as anti-TL1A and anti-IL-23 mechanisms compete with established biologics. The financial logic of both acquisitions is the same: use Keytruda's cash generation to acquire late-stage or commercializing assets that can compound into multi-billion-dollar franchises before the Keytruda patent cliff arrives in 2028. The combined $22 billion represents Merck's largest strategic bet since the Schering-Plough acquisition — and its success will be measured by whether tulisokibart and Winrevair can generate sufficient revenue to partially offset the Keytruda cliff.
Merck's market capitalization of approximately $215 billion against $63.6 billion in fiscal year 2024 revenue implies a price-to-sales ratio of roughly 3.4x and a price-to-earnings ratio of approximately 14–16x forward earnings. This valuation is relatively modest compared to pharmaceutical peers that face less concentrated patent cliff risk — AstraZeneca, for example, trades at higher multiples reflecting a more diversified late-stage pipeline. The discount embedded in Merck's valuation reflects market uncertainty about two questions: how aggressively biosimilar manufacturers will erode Keytruda revenue after 2028, and whether Merck's post-cliff pipeline — Winrevair, tulisokibart, the Daiichi Sankyo ADC partnership, and internal programs — can replace the revenue gap. Bulls argue that biologics erode slowly, that Merck's subcutaneous Keytruda formulation will capture new patients even after biosimilar entry, and that the IBD and PAH franchises are dramatically undervalued. Bears argue that a drug generating $25+ billion from a single company with $63 billion total revenue creates earnings risk that no pipeline can fully hedge. The Vioxx settlement — $4.85 billion — and the ongoing Gardasil China headwind are additional variables that weigh on valuation. Merck's financial complexity makes it one of the most analyzed valuations in large-cap healthcare.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Merck & Co., Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/merck/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Merck & Co., Inc. reported $65B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/merck/financials" target="_blank" rel="noopener">CorpDigest — Merck & Co., Inc. financials</a></div>